Archive
A tighter archive for life-science signals.
Search once, then narrow by source or topic.
Novo Nordisk launches Wegovy pill at $25 per month for insured patients, $149 cash
Novo Nordisk launches Wegovy pill at $25 per month for insured patients, $149 cash
Novo Nordisk’s weight loss pill approved by FDA
Don't miss tomorrow's biopharma industry news Let BioPharma Dive's free newsletter keep you informed, straight from your inbox. By signing up to receive our newsletter,...
Novo Nordisk eyes a strong launch with FDA approval of obesity pill
Novo Nordisk eyes a strong launch with FDA approval of obesity pill
Novo Nordisk hit with FDA warning letter over acquired Catalent factory
Novo Nordisk hit with FDA warning letter over acquired Catalent factory
<a href="https://www.fiercebiotech.com/pharma/novos-shares-tumble-8-after-2-trial-misses-semaglutide-alzheimers-disease" hreflang="en">Novo shares tumble after 2 trial misses for semaglutide in Alzheimer's disease</a>
Novo Nordisk has come up short in two phase 3 trials of semaglutide as a treatment for Alzheimer’s disease. But perhaps the larger story associated with the unsurprisin...
Novo Nordisk’s amycretin cuts body weight, blood sugar in Phase 2 diabetes trial
Novo Nordisk’s amycretin cuts body weight, blood sugar in Phase 2 diabetes trial
Novo Nordisk's semaglutide misses in closely-watched Alzheimer’s trials
Novo Nordisk’s bet on semaglutide in Alzheimer’s disease was always a long shot, and like most long shots, it has missed the mark. The GLP-1 agonist failed to delay dis...
Novo’s semaglutide fails in phase III Alzheimer’s trials
Novo Nordisk A/S’ wild card bet that its GLP-1 receptor agonist semaglutide could be used to treat Alzheimer’s disease has not paid off, with the company reporting two...